Abby Hardy, Author at BioTuesdays

Developments

Verona Pharma initiates Phase 2 trial for COPD inhaler

Verona Pharma (NASDAQ:VRNA) initiated a Phase 2 trial of its metered-dose inhaler (MDI) formulation of ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Ensifentrine inhibits...

June 4, 2019

Developments

Zenabis posts Q1 net revenue of $11.6-million; anticipates range of $26-millon to $30-million for Q2

Zenabis Global (TSX:ZENA) posted net revenue of $11.6-million from its cannabis and propogation segment for the first quarter of 2019, up from $3.4-million in the fourth quarter of 2018, which included only its cannabis...

May 31, 2019

Markets

Roth starts Five Prime Therapeutics at neutral; PT $10

Roth Capital Partners launched coverage of Five Prime Therapeutics (NASDAQ:FPRX) with a “neutral” rating and $10 price target. The stock closed at $8.73, down 32 cents, on May 28.

May 29, 2019

Feature

Oragenics developing novel therapeutics using synthetic bacteria

By Abby Hardy Oragenics (NYSE American: OGEN) is leveraging its synthetic biology platforms to address two significant unmet medical needs: oral mucositis (OM) and multi drug-resistant (MDR) bacterial infections...

May 28, 2019

Markets

HCW ups Aurinia price target to $25

H.C. Wainwright raised its price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) to $25 from $15 after assessing the value of the company’s recently-received new dosing regimen patent. The stock closed at $6.49 on May...

May 23, 2019

Developments

Brookline Capital in partnership with Arcadia Securities

Investment banker Brookline Capital Markets entered into a partnership with broker-dealer, Arcadia Securities. The transaction allows Brookline to capitalize on and expand its growing presence in the public capital...

May 22, 2019

Developments

BeyondSpring presents bone pain relief abstract for Plinabulin at ISPOR

BeyondSpring’s (NASDAQ:BYSI) abstract on its lead asset, Plinabulin, has been accepted for poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 2019 conference May 18-22 in New...

May 21, 2019

Developments

Compugen doses first patient in advanced solid tumor trial

Compugen (NASDAQ:CGEN) dosed the first patient in its Phase 1 trial of COM701, in combination with Opdivo, in patients with advanced solid tumors. The Phase 1 study will assess the safety and tolerability of COM701, a...

May 21, 2019

Developments

Achillion reports positive interim Phase 2 data in paroxysmal nocturnal hemoglobinuria

Achillion Pharmaceuticals (NASDAQ:ACHN) reported interim data from its Phase 2 trial of ACH-4471, in combination with eculizumab, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). In PNH, the complement...

May 17, 2019

Developments

MacroGenics reports positive Phase 3 results in HER2-positive metastatic breast cancer

MacroGenics’ (NASDAQ:MGNX) Phase 3 trial of margetuximab met its first sequential primary endpoint of progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer. The median PFS of patients...

May 16, 2019

Author - Abby Hardy

Verona Pharma initiates Phase 2 trial for COPD inhaler

Zenabis posts Q1 net revenue of $11.6-million; anticipates range of $26-millon to $30-million for Q2

Roth starts Five Prime Therapeutics at neutral; PT $10

Oragenics developing novel therapeutics using synthetic bacteria

HCW ups Aurinia price target to $25

Brookline Capital in partnership with Arcadia Securities

BeyondSpring presents bone pain relief abstract for Plinabulin at ISPOR

Compugen doses first patient in advanced solid tumor trial

Achillion reports positive interim Phase 2 data in paroxysmal nocturnal hemoglobinuria

MacroGenics reports positive Phase 3 results in HER2-positive metastatic breast cancer

Subscribe